75n98026q00716

Background
The National Cancer Institute (NCI) is seeking to engage Moffitt Cancer Center & Research Institute for a specialized project focused on the corrective editing of splicing factor mutant myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).
The NCI's mission involves advancing cancer research and treatment, and this contract aims to leverage Moffitt's unique capabilities in this specific area of hematologic malignancies.

Work Details
The work involves corrective editing related to splicing factor mutant MDS and CMML.
Moffitt Cancer Center & Research Institute is recognized for its expertise in the biology and treatment of these conditions, possessing specialized clinical, scientific, and translational research capabilities.
Key aspects include:
- Access to one of the largest referral populations of patients with MDS and CMML in the U.S., providing necessary patient specimens for research.
- Established expertise in developing patient-derived xenograft (PDX) models for hematologic malignancies, along with the technical personnel required for model generation and evaluation.
- An integrated clinical and research infrastructure that allows for efficient patient evaluation, specimen procurement, cellular manipulation, and transplantation into mouse models within a single institution, thus preserving sample viability and reducing logistical complexities.

Place of Performance
12902 Magnolia Drive Tampa FL 33612

Bidder Requirements
Moffitt Cancer Center & Research Institute is deemed uniquely qualified due to its specialized expertise and resources.
While this notice does not request competitive quotations, any responsible source including small businesses may submit a capability statement demonstrating their ability to meet the requirements.
However, it is indicated that no other source possesses the combination of clinical expertise, patient access, PDX capabilities, and integrated research infrastructure necessary for this project.